XUHC:F:F-Xtrackers (IE) Public Limited Company - Xtrackers MSCI USA Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 55.59

Change

+0.14 (+0.25)%

Market Cap

USD 0.85B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-07 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.14 (+0.52%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.17 (+0.33%)

USD 114.95B
SXR8:F iShares Core S&P 500 UCITS ETF..

+1.56 (+0.27%)

USD 98.13B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.21 (+0.38%)

USD 91.82B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.36 (+2.42%)

USD 54.47B
VUSA:F Vanguard Funds Public Limited ..

N/A

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.33 (+0.31%)

USD 51.63B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 50.58B
XJSE:F Xtrackers II - Japan Governmen..

+0.04 (+0.56%)

USD 40.89B
0ZC:F Zscaler Inc

-3.02 (-1.67%)

USD 37.92B

ETFs Containing XUHC:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.83% 60% D- 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.83% 60% D- 63% D
Trailing 12 Months  
Capital Gain 16.36% 54% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.36% 54% F 59% D-
Trailing 5 Years  
Capital Gain 63.64% 81% B- 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.64% 81% B- 75% C
Average Annual (5 Year Horizon)  
Capital Gain 10.75% 74% C 69% C-
Dividend Return 10.75% 72% C 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.72% 63% D 87% B+
Risk Adjusted Return 100.23% 95% A 96% N/A
Market Capitalization 0.85B 74% C 56% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike